Rozanolixizumab for Generalized Myasthenia Gravis

Treatment with rozanolixizumab, a subcutaneous form of neonatal Fc receptor inhibitor, resulted in clinically meaningful improvements and was generally well tolerated.

Blockade of the neonatal Fc receptor (FcRn) has been shown to be an effective treatment for patients with generalized myasthenia gravis (MG). In a prior phase 3 study, intravenous therapy with the recently FDA-approved FcRn inhibitor efgartigimod was safe and efficacious in patients with generalized MG (NEJM JW Neurol Jul 12 2021 and Lancet Neurol 2021; 20:526). Now, investigators have conducted an industry-funded, international, randomized, double-blind, phase 3 trial (MycarinG) trial to evaluate the efficacy and safety of an investigational FcRn inhibitor, rozanolixizumab, in this setting. A total of 200 patients with MG were assigned (1:1:1) to receive once-weekly subcutaneous infusions of 7 mg/kg of rozanolixizumab, 10 mg/kg of rozanoli…

Reviewing Author

Mohammad Khoshnoodi, MD

Rozanolixizumab for Generalized Myasthenia Gravis

Topics

Reviewing Author